HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Section

Pipeline

Late-stage drugs with significant commercial implications

PipelineAJMC ↗
May 22, 2026
Lilly’s triple-G drug helps patients lose roughly a quarter of weight, showcasing competitive profile
PipelineFierceBiotech ↗
As Eli Lilly looks to hold its lead in the lucrative obesity market, the company’s next-gen prospect, the trip…
May 22, 2026
STAT+: Merck-Kelun lung cancer drug cut risk of tumor progression by 65%, ASCO abstract shows
PipelineSTAT News ↗
A type of targeted chemotherapy developed by China-based Kelun-Biotech and licensed to Merck cut the risk of t…
May 21, 2026
Merck and Kelun’s sac-TMT Clears Key Phase 3 Hurdle in Endometrial Cancer
PipelineBriefing
The global phase 3 win gives Merck’s sacituzumab tirumotecan fresh momentum across 17 ongoing ADC trials, offe…
May 21, 2026
ATS 2026: Long-term data show durable benefit of Trikafta for cystic fibrosis
PipelinePharmaceutical Technology ↗
48 weeks of Trikafta treatment improved lung capacity and inflammation biomarkers among CF patients.…
May 21, 2026
STAT+: Pioneering trial for treating genetic disease before birth nears reality
PipelineSTAT News ↗
A UCSF team has submitted an application to the FDA seeking approval for a small trial of in utero gene therap…
May 20, 2026
← Newer Page 2 Older →
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.